Search results
Results from the WOW.Com Content Network
The transplant is called an allograft, allogeneic transplant, or homograft. Most human tissue and organ transplants are allografts. It is contrasted with autotransplantation (from one part of the body to another in the same person), syngenic transplantation of isografts (grafts transplanted between two genetically identical individuals) and ...
Donor specific antigens are recognized by recipient’s T lymphocytes and triggers adaptive pro-inflammatory response which consequently leads to rejection of allogenic transplants. Allospecific T lymphocytes may be stimulated by three major pathways: direct recognition, indirect recognition or semidirect recognition.
Graft-versus-host disease (GvHD) is an inflammatory disease that is unique to allogeneic transplantation. It is an attack by the "new" bone marrow's immune cells against the recipient's tissues. This can occur even if the donor and recipient are HLA-identical because the immune system can still recognize other differences between their tissues.
Autologous stem-cell transplantation is distinguished from allogenic stem cell transplantation where the donor and the recipient of the stem cells are different people. [2] It can be also used as an Assisted reproductive technology to improve the reproductive outcomes. In a first step the bone marrow derived stem cells are mobilized.
allogeneic, referring to allotransplantation or an allograft (from other individual of same species). xenogeneic , referring to xenotransplantation or a xenograft (from other species). References
In allogeneic cell therapy the donor is a different person to the recipient of the cells. [27] In pharmaceutical manufacturing, the allogenic methodology is promising because unmatched allogenic therapies can form the basis of "off the shelf" products. [28]
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today announced that Benjamin M. Beneski has been promoted to Senior Vice President and Chief Technical Officer (CTO).
Alloimmunity is caused by the difference between products of highly polymorphic genes, primarily genes of the major histocompatibility complex, of the donor and graft recipient. These products are recognized by T-lymphocytes and other mononuclear leukocytes which infiltrate the graft and damage it.